Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC HR97 TFA | 1518.84 | 5 MG
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery.
- Cell-penetrating peptide
- Molecular weight of 1518.84 (free acid)
- Sequence: Phe-Ser-Gly-Lys-Arg-Arg-Lys-Arg-Lys-Pro-Arg-Cys
- Solubility in DMSO: 50 mg/mL (requires ultrasonic)
- Can be used to prepare HR97-SunitiGel eye drops
Medchemexpress LLC Nls-Stax-h (Tfa) | 2872559-21-0 | 98.9% | 3559.28 | 100 UG
Nls-Stax-h is a selective, cell-permeable, stapled peptide that acts as a Wnt signaling inhibitor. It has an Ic50 of 1.4 μM and effectively inhibits β-catenin-transcription factor interactions. This compound demonstrates anti-proliferative effects on cancer cells.
- Selective Wnt signaling inhibitor.
- Cell-permeable.
- Stapled peptide.
- Inhibits β-catenin-transcription factor interactions.
- Shows anti-proliferation of cancer cells.
- Inhibits proliferation of colorectal cancer cells at 10 μM over 72 h, reducing viability by more than 80% in SW-480 and DLD-1 cells.
- Inhibits migration of colorectal cancer cells at 5 and 10 μM over 24 h, resulting in dose-dependent inhibition of wound closure (52% at 5 μM, and 24% at 10 μM in DLD-1 cells).
Medchemexpress LLC CRA-2059 TFA | 99.9% | 864.83 | 1 ML
CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ). Tryptase is a trypsin-like serine protease found as a major protein component in human mast cell secretory granules. CRA-2059 has the potential for inflammatory bowel disease research.
- Highly specific and selective tryptase inhibitor
- Potential for inflammatory bowel disease research
- Inhibits recombinant human tryptase-β (rHTβ) with a Ki of 620 pM
- Targets tryptase, a trypsin-like serine protease
Medchemexpress LLC Sar441255 TFA | 99.93% | 4866.56 (free base) | 5 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It displays high potency with balanced activation of all three target receptors and shows positive acute glucoregulatory effects in diabetic obese monkeys. This product is for research use only.
- Potent unimolecular peptide
- GLP-1/GIP/GCG receptor triagonist
- Displays high potency
- Balanced activation of target receptors
- Shows positive acute glucoregulatory effects
- For research use only
Medchemexpress LLC DX600 TFA | 99.2% | 3074.33 (free acid) | 1 MG
DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM) that does not cross-react with ACE. It has been observed to exacerbate diabetes-induced cardiovascular dysfunction and increase cardiac and renal NOX activity. It is for research use only.
- Selective ACE2 specific inhibitor
- Does not cross-react with ACE
- Exacerbates diabetes-induced cardiovascular dysfunction
- Increases cardiac and renal NOX activity
Medchemexpress LLC Clovibactin TFA | 97.1% | 903.08 | 100 UG
Clovibactin TFA is the TFA salt form of Clovibactin. It is an antibiotic effective against drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inhibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors.
- Effective against drug-resistant bacterial pathogens
- Exhibits no detectable resistance
- Inhibits cell wall synthesis
- Targets pyrophosphate of peptidoglycan precursors
Medchemexpress LLC F11R peptide TFA | 97.6% | 1459.58 | 5 MG
F11R peptide TFA is an F11 receptor molecule that inhibits anti-F11R antibody-induced platelet aggregation and the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells. It can be used for research of atherosclerotic plaques and associated thrombotic disease.
- Inhibits anti-F11R antibody-induced platelet aggregation.
- Inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflamed endothelial cells.
Medchemexpress LLC BRP TFA (BRINP2-related peptide TFA) | 1540.88 (free base) | 1 MG
BRP (BRINP2-related peptide) TFA possesses anti-obesity activity via FOS activation. This peptide activates FOS in the central nervous system and acts independently of leptin, GLP-1 receptor, and melanocortin 4 receptor. It is intended for research use only.
- Anti-obesity activity
- FOS activation
- Activates FOS in the central nervous system
- Acts independently of leptin
- Acts independently of GLP-1 receptor
- Acts independently of melanocortin 4 receptor
Medchemexpress LLC NLS-StAx-h TFA | 98.9% | 3559.28 | 1 MG
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide that inhibits Wnt signaling, with an IC50 of 1.4 μM. It effectively inhibits interactions between β-catenin and transcription factors and demonstrates anti-proliferative effects on cancer cells, including SW-480 and DLD-1 colorectal cancer cells.
- Selective, cell permeable, stapled peptide
- Inhibits Wnt signaling with an IC50 of 1.4 μM
- Efficiently inhibits β-catenin-transcription factor interactions
- Shows anti-proliferation of cancer cells
- Inhibits proliferation of colorectal cancer cells (SW-480 and DLD-1 cells) by more than 80% at 10 μM
- Inhibits migration of DLD-1 colorectal cancer cells in a dose-dependent manner
Medchemexpress LLC Fsllry-nh2 tfa | 245329-02-6 | 99.7% | 910.98 | 10 MG
FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor used for research purposes. Treatment with FSLLRY-NH2 has been shown to significantly improve neurological outcome and reduce the number of degenerating hippocampal neurons after ACA (asphyxial CA).
- Protease-activated receptor 2 (PAR2) inhibitor
- Significantly improves neurological outcome after cardiac arrest in rats
- Reduces degenerating hippocampal neurons after asphyxial CA
- For research use only
Medchemexpress LLC D-GsMTx4 TFA | 99.9% | 4095.84 | 100 UG
D-GsMTx4 TFA is a spider peptide and the D enantiomer of GsMTx4. It inhibits the mechanosensitive ion channel Piezo2, [Ca2+]i elevation, and mTOR and PI3K-Akt signaling pathways. This compound can inhibit mechanical allodynia and thermal hyperalgesia.
- Inhibits the mechanosensitive ion channel Piezo2.
- Inhibits intracellular calcium elevation.
- Inhibits mTOR and PI3K-Akt signaling pathways.
- Can be used in research related to mechanical stress.
- Useful for studies on chronic pain and idiopathic pulmonary fibrosis.
Medchemexpress LLC Peptide5 TFA | 98.9% | 1509.60 | 1 MG
A connexin 43 mimetic peptide, it reduces animal swelling, astrogliosis, and neuronal cell death after spinal cord injury. It also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent.
- Reduces animal swelling after spinal cord injury.
- Reduces astrogliosis after spinal cord injury.
- Reduces neuronal cell death after spinal cord injury.
- Inhibits NLRP3 inflammasome.
- Acts as an anti-inflammatory agent.
Medchemexpress LLC Ala-MPSD TFA | 98.02% | 3016.76 | 5 MG
Ala-MPSD TFA is a control peptide for MPSD (HY-P10471). In Ala-MPSD TFA, the four serine residues of MPSD are substituted by alanines.
- Control peptide for MPSD (HY-P10471)
- Four serine residues of MPSD are substituted by alanines
- Molecular formula: C147H243N41O27.XC2HF3O2
- Sequence: Lys-Lys-Lys-Lys-Lys-Arg-Phe-Ala-Phe-Lys-Lys-Ala-Phe-Lys-Leu-Ala-Gly-Phe-Ala-Phe-Lys-Lys-Asn-Lys-Lys
- Purity: 98.02% (HPLC)
- Appearance: White to off-white (solid)
- MS consistent with structure
Medchemexpress LLC mP6 (TFA) | 2700321-79-3 | 990.15 | 1 MG
mP6 (Myr-FEEERA-OH) is a myristoylated peptide that functions as an Integrin β(3) Inhibitor. It inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. Additionally, mP6 blocks the GTP usage of Rac1, Rap1, and Rab7, which effectively inhibits the infection of CHO-A24 cells.
- Myristoylated peptide
- Functions as an Integrin β(3) Inhibitor
- Inhibits the interaction of Gα13 with integrin β3
- Does not disrupt talin-dependent integrin function
- Blocks the GTP usage of Rac1, Rap1, and Rab7
- Effectively inhibits the infection of CHO-A24 cells
Medchemexpress LLC Cyclo(RLsKDK) TFA | 99.7% | 841.88 | 1 MG
Cyclo(RLsKDK) TFA is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. It is utilized in research for inflammatory diseases and cancer studies.
- Specific inhibitor of metalloproteinase ADAM8 (IC50 182 nM).
- Promotes ADAM8 activation and CD23 shedding (IC50 120 nM and 182 nM).
- Increases activity of pro-ADAM8.
- Reduces tumor load and improves survival rates in pancreatic ductal adenocarcinoma (PDAC) mice models.
- Reduces sADAM8 content, pERK1/2 activation, and PDAC metastasis in vivo.